地塞米松12 mg与6 mg治疗COVID-19合并严重低氧血症患者的长期结局
该研究为COVID STEROID 2试验的长期随访分析,纳入欧洲和印度26家医院1000例确诊COVID-19且接受至少10 L/min氧气或无创/有创机械通气的成人患者,随机接受地塞米松12 mg或6 mg每日一次最多10天。180天时,12 mg组486例中164例(33.7%)死亡,6 mg组477例中184例(38.6%)死亡,校正风险差-4.3%(99%CI -11.7至3.0),相对风险0.89(0.72-1.09),P=0.13。EQ-5D-5L指数值校正均值差0.06(99%CI -0.01至0.12,P=0.10),EQ VAS评分校正均值差4分(99%CI -3至10,P=0.22)。结论认为两组在180天死亡率和健康相关生活质量方面无统计学显著差异,但结果最符合高剂量获益。
要点
- 180天死亡率:地塞米松12 mg组33.7%(164/486) vs 6 mg组38.6%(184/477),校正风险差-4.3%(99%CI -11.7至3.0),RR 0.89(0.72-1.09),P=0.13。
- 180天EQ-5D-5L指数值校正均值差0.06(99%CI -0.01至0.12),P=0.10;EQ VAS评分校正均值差4分(99%CI -3至10),P=0.22。
- 研究纳入接受至少10 L/min氧气或机械通气的COVID-19成人患者,地塞米松12 mg或6 mg每日一次最多10天。
- 作者认为结果最符合高剂量地塞米松获益,但未达统计学显著。
适用人群与场景
- 确诊COVID-19且接受至少10 L/min氧气或无创/有创机械通气的成人患者,来自欧洲和印度26家医院。
处置流程与药物剂量
- 地塞米松12 mg每日一次,最多10天。
- 地塞米松6 mg每日一次,最多10天。
研究设计与关键结果
- 研究类型:国际、分层、盲法随机对照试验(COVID STEROID 2)的长期随访分析;样本量1000例,来自欧洲和印度26家医院。
- 干预与对照:地塞米松12 mg vs 6 mg,每日一次,最多10天。
- 主要终点:180天死亡率,12 mg组33.7%(164/486) vs 6 mg组38.6%(184/477),校正风险差-4.3%(99%CI -11.7至3.0),RR 0.89(0.72-1.09),P=0.13。
- 关键次要终点:EQ-5D-5L指数值校正均值差0.06(99%CI -0.01至0.12),P=0.10;EQ VAS评分校正均值差4分(99%CI -3至10),P=0.22。
- 数据完整性:意向性治疗人群982例中963例(98.1%)获得180天生存状态,922例(93.9%)获得EQ-5D-5L指数值数据,924例(94.1%)获得EQ VAS数据。
证据类型、等级与局限
- 证据类型:随机对照试验的长期随访分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于COVID-19合并严重低氧血症(接受至少10 L/min氧气或机械通气)的成人患者,地塞米松12 mg与6 mg相比在180天死亡率和健康相关生活质量上无统计学显著差异,但作者认为结果最符合高剂量获益。
指南或共识出处
- COVID STEROID 2试验的长期随访分析,发表于Intensive Care Medicine。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.
METHODS: We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero.
RESULTS: We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22).
CONCLUSION: Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.
参考来源
- Granholm A, Kjær MN, Munch MW, et al. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive Care Med. 2022. PMID: 35359168. doi:10.1007/s00134-022-06677-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。